| 價格 | ¥228 | ¥546 | ¥753 |
| 包裝 | 1mg | 5mg | 10mg |
| 最小起訂量 | 1mg |
| 發(fā)貨地 | 上海 |
| 更新日期 | 2026-06-29 |
| 中文名稱:化合物 Encequidar mesylate | 英文名稱:Encequidar mesylate |
| CAS:849675-87-2 | 品牌: TargetMol |
| 產(chǎn)地: 美國 | 保存條件: Keep away from moisture, Pure form: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 純度規(guī)格: 99.84% | 產(chǎn)品類別: 抑制劑 |
| 貨號: T001|T11578L |
| 名稱 | Encequidar mesylate |
| 描述 | Encequidar mesylate (HM30181A mesylate) is a competitive P-glycoprotein inhibitor. |
| 體外活性 | Treatment of 0.1 or 1 nM Encequidar lead to 20 and 42% inhibition of survival at the 100 nM and 1000 nM NSC 125973 treatment, respectively [2]. |
| 體內(nèi)活性 | The plasma concentrations of Encequidar are higher for the simultaneous administration with the microcapsule than with the powder; providing significant differences from 1 to 2 h. The microcapsule has about a 1.7-fold faster Tmax and a 1.6-fold higher AUC value compared with the powder (2.5±0.6 vs. 4.3±0.9 h; 107.7±20.1 vs. 64.3±18.0 h ng/mL). The faster and overall improved absorption of Encequidar in microcapsule form might be due to the remarkable enhancement of the aqueous solubility and dissolution resulting from its crystalline conversion to the amorphous form and particle size reduction [1]. |
| 存儲條件 | Keep away from moisture, Pure form: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | 10% DMSO+90% Saline : 6.25 mg/mL (7.96 mM), Suspension. DMSO : 62.5 mg/mL (79.64 mM), Sonication is recommended. |
| 關(guān)鍵字 | P-gp?(P-glycoprotein) | P-gp | Pgp | P-glycoprotein | Multidrug resistance protein 1 | MDR1 | Inhibitor | inhibit | HM30181A Mesylate | HM30181A | HM-30181 Mesylate | HM30181 Mesylate | HM-30181 | HM30181 | HM 30181 Mesylate | HM 30181 | Encequidar Mesylate | Encequidar | Cluster of differentiation 243 | CD243 | ABCB1 |
| 相關(guān)產(chǎn)品 | Bisdemethoxycurcumin | Trifluoperazine dihydrochloride | Tariquidar | Cinchonine | P-gp inhibitor 1 | Glibenclamide | Bifendate | Verapamil hydrochloride | Atazanavir | Polyoxyethylene stearate | Atazanavir sulfate | 1-piperoylpiperidine |
| 相關(guān)庫 | 抑制劑庫 | 經(jīng)典已知活性庫 | 抗癌活性化合物庫 | 已知活性化合物庫 | ReFRAME 相關(guān)化合物庫 | 神經(jīng)信號分子庫 | NO PAINS 化合物庫 | 臨床期小分子藥物庫 | 膜蛋白靶向化合物庫 | 藥物功能重定位化合物庫 | 抗癌臨床化合物庫 | 抗癌藥物庫 |
| 成立日期 | 2013-04-18 (14年) | 注冊資本 | 566.265100萬人民幣 |
| 員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
| 主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
| 產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
|---|---|---|---|---|
| 詢價 |
VIP7年
|
南昌探真生物技術(shù)有限公司
|
2026-07-17 | |
| 詢價 |
VIP5年
|
陜西締都醫(yī)藥化工有限公司
|
2026-06-05 | |
| ¥12500 |
鄭州灝德醫(yī)藥科技有限公司
|
2026-07-15 | ||
| 詢價 |
VIP11年
|
上海芮暉化工科技有限公司
|
2026-07-15 |